INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE
Status:
Not yet recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
China has the largest burden of cerebrovascular disease in the world. About 60% to 80% of
which are ischemic stroke. In recent years, stroke has replaced heart disease and tumor
diseases as the first cause of death and disability in adult population. The primary purpose
of this study is to evaluate the efficacy of indobufen treatment in reducing the risk of a
3-month new stroke (any type of stroke, including ischemic stroke and hemorrhagic stroke) for
patients with moderate/severe ischemic stroke is not inferior to aspirin therapy.
Phase:
Phase 4
Details
Lead Sponsor:
Ministry of Science and Technology of the People´s Republic of China